Zevra director exercises options for 78,400 shares

Zevra Therapeutics director John B. Bode exercised stock options to acquire 78,400 shares of common stock.

Rhea-AI Filing Summary

Zevra Therapeutics director John B. Bode exercised stock options to acquire 78,400 shares of common stock. On March 24, 2026, he exercised two option grants covering 39,200 shares each at exercise prices of $4.97 and $4.89 per share.

Following these exercises, Bode directly owns 123,400 shares of Zevra Therapeutics common stock. The transactions were reported as derivative exercises rather than open-market purchases or sales, indicating a shift from options-based compensation into outright share ownership.

Insider Trade Summary

78,400 shares exercised/converted

Exercise 4 txns

Insider Bode John B

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	39,200	$0.00	$0.00
Exercise	Stock Option (right to buy)	39,200	$0.00	$0.00
Exercise	Common Stock	39,200	$4.97	$195K
Exercise	Common Stock	39,200	$4.89	$192K

Holdings After Transaction: Stock Option (right to buy) — 19,600 contracts (Direct); Common Stock — 123,400 shares (Direct)

Footnotes (2)

1. F1. The remaining shares underlying this option, which was granted on May 3, 2023, will vest one day prior to the date of the third annual meeting of the Issuer's stockholders following the day of the grant, subject to the Reporting Person's continued service as a director.
2. F2. The shares underlying this option, which was granted on May 13, 2024, were fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did John B. Bode report in his latest Form 4 for ZVRA?

John B. Bode reported exercising stock options to acquire 78,400 Zevra Therapeutics shares. He exercised two option grants of 39,200 shares each, converting options into common stock rather than trading shares in the open market.

How many Zevra Therapeutics (ZVRA) shares does John B. Bode now hold?

After the reported transactions, John B. Bode directly owns 123,400 Zevra Therapeutics common shares. This reflects the addition of 78,400 shares acquired through option exercises on March 24, 2026, as disclosed in the Form 4 filing.

Were any Zevra Therapeutics (ZVRA) shares sold in this Form 4 filing?

No shares were reported sold. All transactions were coded as option exercises, meaning Bode converted stock options into 78,400 common shares. The filing contains no open-market sales or tax-withholding dispositions related to these transactions.

At what prices did John B. Bode exercise his ZVRA stock options?

Bode exercised two sets of stock options at fixed exercise prices of $4.97 and $4.89 per share. Each grant covered 39,200 underlying shares, resulting in 78,400 Zevra Therapeutics common shares acquired through these option exercises.

What type of transactions are shown in this ZVRA Form 4 filing?

All reported transactions are derivative exercises, coded as “M” for option exercises. They reflect converting stock options into common shares, not buying or selling stock in the open market, and are typical for equity-based director compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/26/2026 - 08:27 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bode John B

(Last) (First) (Middle)

C/O ZEVRA THERAPEUTICS, INC.

101 FEDERAL STREET

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/24/2026		M		39,200	A	$4.97	84,200	D
Common Stock	03/24/2026		M		39,200	A	$4.89	123,400	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.97	03/24/2026		M			39,200	(1)	05/02/2033	Common Stock	39,200	$0	19,600	D
Stock Option (right to buy)	$4.89	03/24/2026		M			39,200	(2)	05/12/2034	Common Stock	39,200	$0	0	D

Explanation of Responses:

1. The remaining shares underlying this option, which was granted on May 3, 2023, will vest one day prior to the date of the third annual meeting of the Issuer's stockholders following the day of the grant, subject to the Reporting Person's continued service as a director.

2. The shares underlying this option, which was granted on May 13, 2024, were fully vested.

Remarks:

	/s/ Timothy J. Sangiovanni, Attorney-in-Fact for John B. Bode	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)